Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 29, 2019
Daily News
October 29, 2019
- Debiopharm on Hunt for Japanese Ally for 1st-in-Class Cancer Drug, Eyes PIII Launch in 2020
October 29, 2019
- To Weather Latuda Cliff, Sumitomo Dainippon Looks to Cash In on Roivant Alliance to Push Priority R&D
October 29, 2019
- CEFP Members Prod Govt to Set Value-Based Target for Generic Promotion, but MHLW Wary
October 29, 2019
- Desalex Resupply Scheduled from Nov. 18: Kyorin
October 29, 2019
- Astellas’ Kidney Injury Med Gets FDA’s Fast Track Status
October 29, 2019
- Insurance Coverage of Cancer Genomic Profiling Tests in Early Stage Is Difficult: MHLW Official
October 29, 2019
- 1,419 ADR Victim Relief Claims Recieved in FY2018: MHLW
October 29, 2019
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…